

26. Study Group on Long-Term Antihypertensive Therapy: A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension—the GLANT Study. *Hypertens Res* 1995; **18**: 235–244.
27. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. *Biometrics* 1975; **31**: 103–115.
28. Ogihara T, Morimoto S, Okaishi K, *et al*: Questionnaire survey on the Japanese guidelines for treatment of hypertension in the elderly: 1999 revised version. *Hypertens Res* 2002; **25**: 69–75.
29. Julius S, Kjeldsen SE, Weber M, *et al*: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004; **363**: 2022–2031.
30. Angeli F, Verdecchia P, Reboldi GP, *et al*: Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. *Am J Hypertens* 2004; **17**: 817–822.
31. Yao K, Sato H, Sonoda R, Ina Y, Suzuki K, Ohno T: Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. *Hypertens Res* 2003; **26**: 569–576.
32. Yao K, Sato H, Ina Y, Suzuki K, Ohno T, Shirakura S: Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats. *Hypertens Res* 2003; **26**: 635–641.